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high proportion of patients gaining or stabilizing BCVA at a 
3-year follow-up.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Pathological myopia is a major cause of legal blindness 
in developed countries  [1] . Choroidal neovascularization 
(CNV) is an important cause of visual loss among highly 
myopic patients with a prevalence of 5–11%  [2, 3] . Patho-
logical myopia is the most common cause of CNV in 
young individuals  [4] . Natural history of myopic CNV is 
considered to be poor, with a high proportion of patients 
having a significant loss of visual acuity  [5–8] . Nowadays, 
photodynamic therapy (PDT) with verteporfin is the only 
approved treatment by regulatory authorities for myopic 
CNV. However, in the VIPm study, treated eyes did not 
achieve the main outcome by the end of the second year 
of follow-up  [9] . Anti-VEGF drugs have been used off-la-
bel to treat myopic CNV. We have published the 6-month 
and 12-month results of myopic CNV treated with intra-
vitreal ranibizumab with good outcomes  [10, 11] . In the 
present study, we report the 36-month follow-up of myo-
pic CNV treated by intravitreal ranibizumab.
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 Abstract 
 Purpose: To evaluate the long-term safety and efficacy of 
intravitreal ranibizumab in the treatment of myopic choroi-
dal neovascularization (CNV).  Methods:  Three-year retro-
spective, nonrandomized, interventional case series. Forty 
eyes of 39 patients with myopic CNV were included; 15 with 
previous photodynamic therapy, and 25 naïve eyes. Best-
corrected visual acuity (BCVA) changes, central foveal thick-
ness (CFT), and number of treatments were assessed, from 
baseline to month 36.  Results: Mean visual acuity improved 
from 55.4 Early Treatment Diabetic Retinopathy Study
(ETDRS) letters at baseline to 59.7 letters at 12 months (p = 
0.07), 61.8 letters at 24 months (p = 0.008) and 63.4 letters at 
36 months (p = 0.039). Twenty-five percent of the patients 
gained  6 15 letters (3 lines) at 12 months, 30% at 24 months 
and 35% at 36 months. There was a mean reduction of 80   m 
in CFT (p  ! 0.001). A mean of 4.1 injections were performed 
in the first year, 2.4 in the second year and 1.1 in the third 
year. Fifty-three percent of the eyes had no need for treat-
ment during the third year of follow-up.  Conclusions: Intra-
vitreal ranibizumab seems to be an effective and safe thera-
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 Patients and Methods 
 A retrospective, institutional study was performed in 40 eyes 
of 39 patients with active subfoveal or juxtafoveal myopic CNV 
treated with an intravitreal injection (nonloading dose) of 0.5 mg 
of ranibizumab and followed for 3 years. 
 Fifteen eyes had previously undergone PDT for myopic CNV 
at least 3 months before the first ranibizumab treatment. No ad-
ditional PDT was performed during the follow-up.
 The inclusion criteria were: (1) highly myopic eyes with a spher-
ical equivalent  6 –6 dpt or an axial length  6 26.5 mm; (2) poste-
rior fundus myopic changes; (3) active subfoveal or juxtafoveal 
CNV on fluorescein angiography; (4) best-corrected visual acuity 
(BCVA)  6 20/400 at baseline, and (5) age over 18 years. The exclu-
sion criteria were: (1) CNV due to other causes than pathological 
myopia; (2) retinal vasculopathies; (3) patients with subfoveal or 
juxtafoveal laser scar; (4) patients with previous treatment with 
other anti-angiogenic drugs (bevacizumab or pegaptanib) or with 
intravitreal triamcinolone or radiation; (6) ocular hypertension or 
glaucoma; (7) concomitant disease in the study eye, including uve-
itis, presence of pigment epithelial tears or rips, acute ocular or 
periocular infection, and central serous chorioretinopathy; (8) 
pregnancy or premenopausal women not using adequate contra-
ception, and (9) patients with recent thromboembolic events.
 Each patient underwent a complete ophthalmic examination 
including BCVA on a standard Early Treatment Diabetic Reti-
nopathy Study (ETDRS) chart, slit-lamp examination, ocular to-
nometry, fundus examination and an optical coherence tomogra-
phy (OCT; OCT Stratus v. 4.0 and Cirrus HD-OCT v. 2.0; Carl 
Zeiss Meditec, Inc., Dublin, Calif., USA) at baseline and then ev-
ery 4–6 weeks during follow-up. Central foveal thickness (CFT) 
was measured automatically by OCT. We subtracted 60   m from 
the value obtained with the Cirrus HD-OCT for comparison with 
the values obtained with Stratus OCT. Fluorescein angiography 
was performed at baseline for all patients and when in doubt about 
CNV activity during follow-up. All patients had evidence of fluo-
rescein angiography leakage at baseline that involved the fovea 
and was responsible for the decrease in visual acuity.
 The need for retreatment was determined by a decrease in 
BCVA and/or metamorphopsia, the presence of intra- or subreti-
nal fluid in the OCT and/or fluorescein angiography subfoveal or 
juxtafoveal leakage.
 Main outcomes were BCVA change (ETDRS letter gain or loss) 
and CFT change measured by OCT during follow-up. The effects 
of previous PDT treatment and age on final visual acuity were 
considered secondary outcomes. 
 The presence of systemic or ocular side effects was evaluated 
at each visit during the follow-up time.
 The study followed the tenets of the Declaration of Helsinki 
and was approved by the university clinic research committee. An 
informed consent document was reviewed and signed by all pa-
tients.
 Statistical analysis was performed by means of a nonparamet-
ric Wilcoxon signed-rank test and two-tailed t test in order to com-
pare continuous variables. Categorical variables were compared 
using the   2 test. The influence of age, sex, previous PDT and num-
ber of treatments on BCVA change was analyzed by means of mul-
tivariate linear regression. A p value  ! 0.05 was considered statisti-
cally significant. All statistical tests were performed using SPSS 
version 16.0.1 software (SPSS Inc., Chicago, Ill., USA). 
 Results 
 Forty eyes of 39 patients (12 men and 27 women; me-
dian age, 55 years; range, 20–89 years) presenting with 
active myopic CNV were included in this study and treat-
ed with at least one injection of ranibizumab. Fifteen eyes 
had previously undergone unsuccessful PDT for myopic 
CNV with a mean of 2.9 sessions. Follow-up was at least 
30 months for all eyes, and 26 eyes reached the 3 years of 
follow-up. 
 Mean BCVA was 55.4 ETDRS letters at baseline, 59.7 
letters at 12 months (p = 0.07), 61.8 letters at 24 months 
(p = 0.008) and 63.4 letters at 36 months (p = 0.039). 
Twenty-five percent of the patients gained  6 15 letters (3 
lines) at 12 months, 30% at 24 months and 35% at 36 
months. An improvement of  6 0 letters occurred in 57.5% 
of the patients at 12 months, 70% at 24 months and 69% 
at 36 months. BCVA worsened by  6 15 letters in only 2 
patients (5%) at 12 months, 3 patients (7.5%) at 24 months 
and 3 patients (11.5%) at 36 months ( fig. 1 ). There was no 
correlation between final BCVA and initial BCVA (p = 
0.07). We analyzed the response to intravitreal ranibi-
zumab at 6 months dividing the patients into three 
groups: responders (gain  6 5 letters); stable (gain be-
tween –4 and 4 letters) and nonresponders (loss  6 5 let-
ters). At 6 months, 48.7% of the eyes were responders, 
30.8% were stable and 20.5% were nonresponders. The 
type of response at 6 months was significantly associated 
with the type of response to intravitreal ranibizumab at 
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 Fig. 1. BCVA change at 12 months (n = 40), 24 months (n = 40) 
and 36 months (n = 26) of follow-up.  
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12 months (p  ! 0.001), 24 months (p  ! 0.001) and 36 
months (p  ! 0.001) ( fig.  2 ). Mean BCVA change at 6 
months was significantly correlated with mean BCVA 
change at 36 months (p  ! 0.001).
 CFT measured by OCT decreased from a mean of 295 
  m (range, 199–630   m) at baseline to 226   m (range, 
115–336   m) at 12 months (p  ! 0.001), 214   m (range, 
99–392   m) at 24 months (p  ! 0.001) and 215   m (range, 
136–457   m) at 36 months (p = 0.001). CFT change at 36 
months was significantly correlated with initial foveal 
thickness (p = 0.001). Age (p = 0.94), sex (p = 0.53) or pre-
vious PDT treatment (p = 0.46) were not correlated with 
CFT change at 36 months. 
 A mean number of 7.6 (range, 2–19) treatments were 
performed during the follow-up time. A mean of 4.1 in-
jections were performed in the first year, 2.4 in the second 
year and 1.1 in the third year. Twenty-five percent of the 
patients only had treatments during the first year of fol-
low-up and 57% of the patients needed no treatment dur-
ing the third year of follow-up. Final BCVA, previous 
PDT, sex and age were not significantly correlated with 
the number of ranibizumab injections (p = 0.77; p = 0.71; 
p = 0.28, and p = 0.55, respectively). Seventy-five percent 
of the patients needed 3 injections at the first 3 visits. 
There was no significant difference in initial BCVA (p = 
0.20), final BCVA (p = 0.89), initial CFT (p = 0.95), final 
CFT (p = 0.10), age (p = 0.78), or total number of treat-
ments (p = 0.11) between patients who had 3 initial injec-
tions and patients who did not. There was no association 
between previous PDT treatment and the need for 3 ini-
tial injections (p = 0.57). 
 A subgroup analysis was performed on eyes with and 
without previous PDT comparing these two groups re-
garding baseline characteristics (age, initial visual acuity, 
initial CFT) and response to intravitreal ranibizumab. 
No statistical difference (p  1 0.05) was found between 
patients previously treated with PDT and naïve patients 
regarding any of the mentioned baseline characteristics, 
mean BCVA and mean CFT during follow-up or the final 
number of treatments. The eyes previously treated with 
PDT ( fig. 3 ) had an improvement in mean BCVA from 
55.4 letters at baseline to 60.8 letters at 12 months (p = 
0.15), 63.9 letters at 24 months (p = 0.057) and 62.3 at 36 
months (p = 0.14). Eyes with no previous PDT had an im-
provement in mean BCVA from 55.3 letters at baseline to 
59.1 letters at 12 months (p = 0.25), 60.6 letters at 24 
months (p = 0.068) and 64.1 letters at 36 months (p = 
0.16). 
 Visual acuity improvement was significantly associ-
ated with age (p = 0.03). Patients aged less than 55 years 
had an improvement in BCVA from 54.1 letters at base-
line to 63.1 letters at 12 months (p = 0.02), 64.1 letters at 
24 months (p = 0.006) and 67.7 letters at 36 months (p = 
0.001). Patients aged 55 or more years had an improve-
ment in BCVA from 56.5 letters at baseline to 56.3 letters 
at 12 months (p = 0.93), 59.3 letters at 24 months (p = 0.42) 
and 57.4 letters at 36 months (p = 0.53). 
 No systemic or ocular side effects were registered dur-
ing follow-up, including endophthalmitis, retinal detach-
ments, ocular hypertension, intraocular inflammation 
and thromboembolic events. 
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 Fig. 2. Types of response to intravitreal ra-
nibizumab (number of eyes). There was a 
significant (p  ! 0.001) association between 
the type of response at 6 months and the 
response at 12 months, 24 months and 36 
months. 6M = 6 months; NR = nonre-
sponders; S = stable; R = responders. 
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 Discussion 
 The introduction of anti-VEGF therapies in ophthal-
mology revolutionized the way we treat the exudative 
form of age-related macular degeneration (AMD). Ra-
nibizumab is an anti-VEGF drug approved by the US 
Food and Drug Administration and the European Medi-
cines Agency for the treatment of neovascular AMD, im-
proving and stabilizing visual acuity of most of these pa-
tients  [12, 13] . Pathophysiology of myopic CNV is differ-
ent from CNV secondary to AMD. However, high levels 
of VEGF seem to be involved in the development of myo-
pic CNV  [14] . In theory, a similar response to AMD is 
expected in patients with myopic CNV treated with in-
travitreal ranibizumab. 
 Previous studies reporting clinical experience with ra-
nibizumab in myopic CNV have shown promising re-
sults. 
 Silva et al. [10, 11] reported the short-term outcomes of 
myopic CNV treated with ranibizumab and then con-
firmed its efficacy at 12 months of follow-up. Mean vi-
sual acuity improved by 8 letters with a final BCVA of 
59.6 letters at 1 year of follow-up. Twenty-four percent of 
the patients gained  6 15 letters at 12 months with a mean 
of 3.6 treatments  [10, 11] . Monés et al.  [15] reported in a 
study of 23 patients a mean gain of 9.53 letters at 12 
months with 27% gaining more than 15 letters. Lalloum 
et al.  [16] included 36 eyes in their study and BCVA im-
proved from 0.2 at baseline to a final BCVA of 0.4 with 17 
months of follow-up. Forty-six percent of the eyes gained 
more than 15 letters. In the present study, visual acuity 
significantly improved with a longer follow-up time. 
Mean BCVA improved from 55.4 letters at baseline to 59.7 
letters at 12 months (p = 0.07), 61.8 letters at 24 months 
(p = 0.008) and 63.4 letters at 36 months (p = 0.039). 
Twenty-five percent of the patients gained  6 15 letters at 
12 months, 30% at 24 months and 35% at 36 months. Eyes 
losing vision at 6 months had a worse visual prognosis. 
They had a much higher possibility of maintaining a neg-
ative score at the end of follow-up. Visual acuity change 
at 6 months can be a predictive factor of visual outcome 
(p  ! 0.001).
 We adopted a nonloading dose treatment protocol 
with a monthly follow-up and then an as-needed treat-
ment regimen, as did the authors of the previously men-
tioned studies. This decision was based on the assump-
tion that the greater improvement in visual acuity is 
achieved after the first injection of ranibizumab  [10, 11, 
17] and the fact that CNV is generally less extensive in 
myopic eyes than in eyes with AMD. These eyes have less 
intra- or subretinal fluid, which may contribute to a bet-
ter response to intravitreal ranibizumab. A mean of 4.1 
injections were performed in the first year, 2.4 in the sec-
ond year and 1.1 in the third year. The number of treat-
ments was not correlated with final visual acuity and no 
predictive factors for the need for retreatment were iden-
tified. Seventy-five percent of the eyes in our study need-
ed 3 injections at the first 3 visits. However, there was no 
significant difference in final visual acuity between pa-
tients who needed 3 initial injections and patients who 
did not (p = 0.89). The final BCVA of the eyes who did not 
need 3 initial injections was 64 letters with a mean of 5.9 
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 Fig. 3. Patient with previous PDT (3 ses-
sions) for myopic CNV. Baseline retinog-
raphy ( a ), initial-phase ( b ) and late-phase 
( c ) fluorescein angiography, and OCT ( d ) 
showing leakage from subfoveal neovas-
cularization. Baseline BCVA of 48 letters. 
OCT at 36 months ( e ) showing subfove-
al hyperreflectivity compatible with the 
presence of a scar with fibrosis and with-
out intra- or subretinal fluid. This patient 
had a total number of 5 treatments and a 
final BCVA of 85 letters. 
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treatments at the end of the 36 months, so we believe that 
the adoption of a loading dose would be excessive, un-
necessary and associated with higher risks. It is still un-
certain which is the most effective treatment regimen for 
myopic CNV, and there are no studies comparing these 
two treatment modalities (loading dose vs. pro re nata) 
in the management of myopic CNV with ranibizumab. 
There are some authors that adopted a loading dose of 
ranibizumab for myopic CNV. Lai et al.  [18] , in a study 
with 16 eyes, noted a mean gain of 3 lines with a mean of 
3.8 treatments at the end of 12 months. Eighty-one per-
cent of the eyes only needed the loading dose. Calvo-
Gonzalez et al. [19] included 67 eyes with myopic CNV 
treated with a loading dose of ranibizumab with a mean 
follow-up of 15.6 months. They noticed a mean gain of 12 
letters at the end of the follow-up with a mean of 4.2 treat-
ments. A total of 53.7% of the eyes received only 3 injec-
tions. 
 We noticed a significant decrease in CFT measured by 
OCT during the follow-up time, with a mean decrease of 
80   m. In our series, a high proportion of patients had 
their baseline CFT measured with a Stratus OCT and 
their final CFT measured with a Cirrus HD-OCT. There 
is a difference in CFT measurement between these two 
OCTs, and this difference depends on the retinal disease 
in study  [20] . CFT measures by Cirrus OCT are greater 
than by Stratus OCT. This difference can be explained by 
the individual segmentation algorithms of the different 
OCTs. Cirrus OCT identifies the thickness of the retina 
based on the distance between the inner limiting mem-
brane and the outer band of the retinal pigment epithe-
lium while Stratus OCT performs the outer alignment at 
the level of the photoreceptor inner/outer segment junc-
tion. To compare the two systems, we have made a con-
version, subtracting 60   m from the value obtained with 
Cirrus HD-OCT  [21, 22] , so we have to be careful with 
the interpretation of our CFT results as there could be 
some residual errors. Myopic CNV has less intra- and 
subretinal fluid, and the choroid is usually very thin in 
these patients, so OCT can sometimes be useless in the 
decision to treat these patients. That is one of the reasons 
why we included metamorphopsias as a retreatment cri-
teria. 
 Visual acuity improvement was obtained in eyes with 
and without previous PDT treatment, with no significant 
difference in visual outcome between these two groups. 
The mechanisms of action of PDT and ranibizumab are 
different, so patients that had undergone unsuccessful 
PDT for myopic CNV still have an opportunity for vi-
sual acuity improvement when treated with ranibizumab 
for their recurrent CNV. Authors like Lalloum et al. [16] 
noticed a significantly higher improvement in visual acu-
ity in naïve patients when compared with patients who 
had undergone previous PDT. They justified their results 
by the fact that PDT is often associated with fibrosis of 
the neovascular membrane and can facilitate the devel-
opment and progression of chorioretinal atrophy.
 A negative significant correlation was observed be-
tween age and final visual acuity (p = 0.03). Patients aged 
less than 55 years had a higher improvement in visual 
acuity when compared with patients aged 55 or more 
years. This relation was also demonstrated in previous 
studies with PDT for myopic CNV  [23, 24] . Younger pa-
tients have smaller neovascular membranes and a health-
ier retinal pigment epithelium able to envelop the CNV. 
On the other hand, older patients have larger areas of
chorioretinal atrophy  [25] and other age-related retinal 
changes that could explain a worse visual prognosis.
 No cases of endophthalmitis, stroke, or retinal detach-
ment were registered during the follow-up. Particular 
care was taken to observe the peripheral retina before 
treatment, and prophylactic topical antibiotics were ad-
ministered before and after the injection.
 In conclusion, our results suggest that intravitreal ra-
nibizumab appears to be safe and effective in the treat-
ment of subfoveal and juxtafoveal myopic CNV. BCVA 
significantly improves by the end of the third year of fol-
low-up with a high proportion of patients gaining or sta-
bilizing visual acuity. Change in BCVA at 6 months can 
be a predictive factor of visual outcome. Younger patients 
seem to have a better prognosis, and no differences were 
identified in visual outcome between naïve patients and 
patients with previous PDT for myopic CNV. A random-
ized, multicentric clinical trial is necessary to definitely 
conclude on the safety and efficacy of intravitreal ranibi-
zumab for CNV in pathological myopia. 
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